Enlaza Therapeutics is a company of Enlaza Therapeutics. Its proprietary War-Lock platform utilizes its advanced synthetic biology technology to incorporate non-natural amino acids with expanded chemical functions into protein drugs, enabling the drug to interact with its target site-specifically. One-way covalent bonding. Its proprietary amino acid subunits can bind to almost all forms of proteins without affecting the therapeutic specificity of the drug on the target. Enlaza Therapeutics announced the completion of $61 million in seed financing, led by Avalon Ventures, with participation from Lightspeed Venture Partners, Frazier Life Sciences and Samsara BioCapital.
This article is transferred from: https://www.itjuzi.com/investevent/13727223
This site is only for collection, and the copyright belongs to the original author.